Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT03146247
NCT03146247WithdrawnPhase 4

Analysis of the Pathogenesis of Itch in Response to Apremilast Therapy in Psoriasis Patients

Diamant Thaci1 site in 1 countryStarted: October 23, 2017Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 4
Status
Withdrawn
Sponsor
Locations
1
Primary Endpoint
Immunoreactive nerve fibers
Study OverviewStudy DesignEligibility CriteriaArms & InterventionsOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

This study aims to identify and describe the presence of itch active molecules in psoriasis and response to treatment with apremilast. This data will be complemented by immunohistochemical data determining nerve ending density and neuropeptide concentrations before and during treatment and correlated with patient reported outcome. It is important to underscore that itch may interfere with various aspects of patient functioning, emotions and social status and should therefore be adequately addressed while treating patients with psoriasis

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Other
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Subjects must be able to understand and communicate with the investigator and comply with the requirements of the study and must give written, signed and dated informed consent before any study related activity is performed.
  • •Subjects must be at least 18 years of age at time of enrollment
  • •Patients with chronic moderate to severe plaque type psoriasis who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet-A light (PUVA)
  • •Subjects must have a score in the numerical rating scale (NRS, see 12.4) >5 at baseline
  • •Women of childbearing potential* and males with female partners of child bearing potential must be ready and able to use highly effective methods of birth control per ICH M3(R2) that result in a low failure rate of less than 1% per year when used consistently and correctly.
  • •Women of childbearing potential are defined as:
  • •Having experienced menarche and
  • •not Postmenopausal (12 months with no menses without an alternative medical cause) and
  • •not permanently sterilized (e.g. tubal occlusion, hysterectomy, bilateral oophorectomy or bilateral salpingectomy)

Exclusion Criteria

  • •Patients with previous treatment with Apremilast
  • •Patients incapable of giving full informed consent.Patients enrolled in other clinical trials
  • •Allergies against Apremilast or any of the inactive ingredients: lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, iron oxide red, iron oxide yellow (20 and 30 mg only) and iron oxide black (30 mg only)
  • •Rifampicin, Phenobarbital, Carbamazepine, Phenytoin, enzalutamid, mitotan or St John's Wort as concomitant medication
  • •Patients with rare hereditary problems of galactose intolerance, lactase deficiency or glucose-galactose malabsorption
  • •Allergy to local anaesthetic or latex
  • •Pregnancy/Lactation
  • •Patients with known HIV infection and active or uncontrolled hepatitis B or C infection
  • •Patients with known disposition for excessive keloid formation or wound healing disorders
  • •Patients with other forms than chronic plaque type psoriasis especially drug-induced psoriasis
  • •Patients who cannot tolerate the complete dose used in this study due to medical conditions e.g. due to kidney insufficiency
  • •Patients with depressive symptom in PHQ-D in visit 1
  • •Concomitant medication that can cause psychiatric symptoms
  • •Psychiatric disorders

Arms & Interventions

One arm

Other

all patients receive same dose and dosing regimen with Apremilast

Intervention: Apremilast;Apremilast;Apremilast 10 MG; 20 MG; 30 MG Oral Tablet (Drug)

Outcomes

Primary Outcomes

Immunoreactive nerve fibers

Time Frame: until week 16

Proportion of patients reaching 50% reduction of PGP 9-5- immunoreactive nerve fibers at visit 6 (week 16) compared to visit 1 (week 0) measured with immunohistochemical methods

Secondary Outcomes

  • PASI improvement(until week 16)

Investigators

Sponsor
Diamant Thaci
Sponsor Class
Other
Responsible Party
Sponsor Investigator
Principal Investigator

Diamant Thaci

Prof. Dr. med

University of Luebeck

Study Sites (1)

Loading locations...

Similar Trials

Completed
Phase 3
Study of the Drug Efalizumab (Raptiva), for Adult Patients With Moderate to Severe Plaque PsoriasisPsoriasis
NCT00115076Rockefeller University31
Completed
Phase 3
Secukinumab Study in PSOriasis Exploring pruRITUS Intensity and Lesional BiomarkersPsoriasis
NCT02362789Novartis Pharmaceuticals132
Active, not recruiting
Phase 1
Study in patients with moderate to severe psoriasis with secukinumab
EUCTR2014-002212-16-DEovartis Pharma GmbH
Completed
Not Applicable
Genomic Study for the Prediction of Efficacy and Adverse Effects of CD11a Monoclonal Antibodies(Raptiva)Psoriasis
NCT00602823National Taiwan University Hospital20
Terminated
Early Phase 1
Cell Responses to IFN-gammaPlaque Psoriasis
NCT01317017Rockefeller University2